CDT Equity Inc. (CDT)
NASDAQ: CDT · Real-Time Price · USD
1.680
+0.140 (9.09%)
At close: Aug 22, 2025, 4:00 PM
1.650
-0.030 (-1.79%)
After-hours: Aug 22, 2025, 6:31 PM EDT

Company Description

CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.

Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products.

The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025.

The company was founded in 2019 and is based in Naples, Florida.

CDT Equity Inc.
CDT Equity logo
CountryUnited States
Founded2019
IndustryBiotechnology
SectorHealthcare
Employees6
CEOAndrew Regan

Contact Details

Address:
4581 Tamiami Trail North, Suite 200
Naples, Florida 34103
United States
Phone646 491 9132
Websiteconduitpharma.com

Stock Details

Ticker SymbolCDT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001896212
CUSIP Number20678X106
ISIN NumberUS20678X1063
Employer ID87-3272543
SIC Code2834

Key Executives

NamePosition
Dr. Andrew ReganFounder, Chief Executive Officer and Director
James BlighCo-Founder, Chief Financial Officer and Director
Dr. David Joszef TapolczayHead of Strategy and Licensing
Dr. Joanne M. HollandChief Scientific Officer

Latest SEC Filings

DateTypeTitle
Aug 18, 2025SCHEDULE 13G/AFiling
Aug 14, 202510-QQuarterly Report
Aug 14, 202510-Q/A[Amend] Quarterly report
Aug 14, 20258-KCurrent Report
Aug 12, 2025424B3Prospectus
Aug 11, 2025S-8Securities to be offered to employees in employee benefit plans
Aug 8, 20258-KCurrent Report
Aug 7, 2025EFFECTNotice of Effectiveness
Jul 31, 2025SCHEDULE 13D/AFiling
Jul 31, 2025S-3Registration statement under Securities Act of 1933